Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | ACLY | P53396 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545216 | 0.89 | POLB (0.54) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL17545078 | 0.83 | RECQL (0.56) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL17545071 | 0.83 | RECQL (0.56) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL21469186 | 0.81 | POLB (0.45) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL19222298 | 0.80 | POLB (0.47) | KMT2APOLBACLYSMN1; SMN2ALDH1A1 | |
| SCHEMBL17545309 | 0.80 | ACLY (0.50) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL19222362 | 0.80 | ACLY (0.50) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL17545350 | 0.80 | ACLY (0.50) | MEN1KMT2APOLBACLYSMN1; SMN2 | |
| SCHEMBL17545353 | 0.77 | ACLY (0.69) | ACLYSMN1; SMN2LMNATP53GAA | |
| SCHEMBL29707979 | 0.77 | ACLY (0.61) | MEN1KMT2AACLYALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO | 2019-11-07 | — | — | US | disclosed |
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | MEN1 1541/4885KMT2A 1720/4885POLB 1517/4885 |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | MEN1 1541/4885KMT2A 1720/4885POLB 1517/4885 |
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | MEN1 1541/4885KMT2A 1720/4885POLB 1517/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | MEN1 1541/4885KMT2A 1720/4885POLB 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.